Progressive anemia following combination therapy with interferon-α and interleukin-2 in a patient with metastatic renal cell carcinoma

Authors


Yukinari Hosokawa md, Department of Urology, Hoshigaoka Koseinenkin Hospital, 4-8-1 Hoshigaoka, Hirakata, Osaka 573-8511, Japan. Email: yukinari46@nyc.odn.ne.jp

Abstract

Abstract  Various toxicities have been observed during the treatment of advanced renal cell carcinoma with interferon-α (IFN-α) and/or interleukin-2 (IL-2). We report a case of severe anemia, which responded well to steroid therapy, in a patient receiving IL-2 plus IFN-α for metastatic renal cell carcinoma.

Ancillary